Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

作者：A. Dezern, S. Thépot, S. de Botton, Andrea Patriarca, Dries Deeren, Jose Miguel Torregrose Diaz, Giovanni Marconi, T. Bernal del Castillo, J. B. Bergua Burgues, Blanca Xicoy, Anna Jonasova, A. Zeidan, S. Dimicoli-Salazar, Célestine Simand, David Valcárcel, M. Díez-Campelo, Wanxing Chai-Ho, Lalit Saini, A. Garnier, K. Geissler, Y. Ofran, Zsolt Nagy, Pramila Krishnamurthy, M. Lübbert, Grzegorz Basak, H. Carraway, D. Sallman, U. Borate, V. Santini, V. Campbell, Pierre Fenaux, T. Braun, Francesco Lanza, J. Zaucha, D. Roth, Sofia Paul, Pourab Roy, Michael Kelly, A. Volkert, Jaime Chisolm, Tanya Abdul Malak, Virginia Klimek, T. Cluzeau · 发表于：Blood Advances · 年份：2025 · DOI：10.1182/bloodadvances.2025016229 · 被引用次数：9 · 研究领域：Medicine

Key Points • In the phase 3 SELECT-MDS-1 trial, CR was similar between arms in pts with higher-risk MDS.• RARA gene overexpression/RARα activation in myeloid malignancies warrants further investigation as biomarker-driven studies are feasible.